RxDoctor Payments Data

Jeffrey Stein, MD

Internal Medicine · Boca Raton, FLNPI 1053485318

Payments from drug & device makers

$6,513in general payments, 2019–2025

Across 337 payments — averaging $19.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • AbbVie$909
  • Amarin Pharma, Inc.$364
  • GSK$340
  • Exact Sciences$337
  • Lilly USA, LLC$267
  • plus $3K from 32 others

What the payments were for

  • Food & beverage$6,513100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,513 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$458,592
Medicare patients
526
Services billed
15,768

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban54$70,878
OzempicSemaglutide39$56,252
Repatha SureclickEvolocumab51$45,896
XareltoRivaroxaban41$42,164
JanuviaSitagliptin Phosphate18$19,072
FarxigaDapagliflozin Propanediol15$13,561
JardianceEmpagliflozin12$11,946
LivaloPitavastatin Calcium13$11,182
VascepaIcosapent Ethyl25$11,151
MounjaroTirzepatide11$9,711
MovantikNaloxegol Oxalate11$6,953
Atorvastatin Calcium358$5,066
Rosuvastatin Calcium227$3,477
Losartan Potassium223$3,450
Amlodipine Besylate365$3,150

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$267$70,87854 claims
Novo NordiskOzempic$248$56,25239 claims
Johnson & JohnsonXarelto$142$42,16441 claims
AstraZenecaFarxiga$1,382$13,56115 claims
Boehringer IngelheimJardiance$251$11,94612 claims
Kowa Pharmaceuticals America, Inc.Livalo$89$11,18213 claims
Lilly USA, LLCMounjaro$267$9,71111 claims
AbbVieSynthroid$909$2,83621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Boca Raton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →